Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2020The Journal of Infectious DiseasesOpen Access

Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied

View Full Paper
Ask AI
Bookmark
Share

Authors

SVSimopekka VänskäFinnish Institute for Health and WelfareTLTapio LuostarinenFinnish Cancer RegistryIBIacopo BaussanoCentre international de recherche sur le cancer

Discussion

Loading...

Member takes

Implication

Randomized trial reveals gender-neutral HPV vaccination markedly enhances herd protection in adolescents, suggesting moderate coverage can eliminate oncogenic strains.

Key Points

  • To assess whether a gender-neutral HPV vaccination strategy provides superior herd effects and eradicates oncogenic HPV types at moderate coverage compared with a girls-only strategy.
  • Randomized 33 Finnish communities into gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms, enrolling consenting boys and girls born 1992–1995 (11,662 of 20,513 and 40,852 of 39,420).
  • Collected cervicovaginal samples from vaccinated and unvaccinated girls at age 18.5 years between 2010 and 2014, typing for 16 HPV types to estimate vaccine efficacy, herd effects, and overall protective effectiveness.
  • Combined trial data with mathematical modeling to project long-term eradication timelines for oncogenic HPV strains across varying coverage levels.
  • Herd effect and protective effectiveness against HPV18/31/33 in the 1995 birth cohort were significant in the gender-neutral arm, proving 150% and 40% stronger, respectively, than in the girls-only arm.
  • Mathematical modeling predicted complete eradication of HPV18/31/33 in adolescents and young adults within 20 years under 75% gender-neutral vaccination coverage.
  • Eventual eradication of HPV16 was predicted at 75% coverage only when applying the gender-neutral strategy.

Cite This Study

Vänskä et al. (2020) studied this question.

synapsesocial.com/papers/6a6f444bac440176ef27f784https://doi.org/10.1093/infdis/jiaa099
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gender‐neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)2018 · 66 citations
  2. 2Impact of gender‐neutral or girls‐only vaccination against human papillomavirus—Results of a community‐randomized clinical trial (I)2017 · 69 citations
  3. 3A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls2013 · 127 citations
  4. 4The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland2018 · 35 citations
  5. 5Declining Genital Warts in Young Women in England Associated With HPV 16/18 Vaccination: An Ecological Study2013 · 75 citations